KR970705979A - 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles) - Google Patents

치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles) Download PDF

Info

Publication number
KR970705979A
KR970705979A KR1019970702043A KR19970702043A KR970705979A KR 970705979 A KR970705979 A KR 970705979A KR 1019970702043 A KR1019970702043 A KR 1019970702043A KR 19970702043 A KR19970702043 A KR 19970702043A KR 970705979 A KR970705979 A KR 970705979A
Authority
KR
South Korea
Prior art keywords
microparticle
water
therapeutic agent
soluble
soluble substance
Prior art date
Application number
KR1019970702043A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 드렉 써튼
리차드 알란 존슨
Original Assignee
디 히스
안다리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 히스, 안다리스 리미티드 filed Critical 디 히스
Publication of KR970705979A publication Critical patent/KR970705979A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019970702043A 1994-09-29 1995-09-26 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles) KR970705979A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94307126.6 1994-09-29
EP94307126 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (1)

Publication Number Publication Date
KR970705979A true KR970705979A (ko) 1997-11-03

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702043A KR970705979A (ko) 1994-09-29 1995-09-26 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles)

Country Status (16)

Country Link
EP (1) EP0783298A1 (no)
JP (1) JPH10506406A (no)
KR (1) KR970705979A (no)
AU (1) AU701440B2 (no)
BR (1) BR9509171A (no)
CA (1) CA2199954A1 (no)
CZ (1) CZ92497A3 (no)
FI (1) FI971332A0 (no)
HU (1) HUT77373A (no)
MX (1) MX9702357A (no)
NO (1) NO971438D0 (no)
NZ (1) NZ292980A (no)
PL (1) PL319600A1 (no)
RU (1) RU2147226C1 (no)
WO (1) WO1996009814A1 (no)
ZA (1) ZA958239B (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
AU702955B2 (en) * 1996-05-17 1999-03-11 Quadrant Healthcare (Uk) Limited Microparticles and their use in wound therapy
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9615435D0 (en) * 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
US5961459A (en) * 1996-10-19 1999-10-05 Andaris Limited Use of hollow microcapsules in diagnosis and therapy
JP2001507700A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ 疎水性エアゾール薬剤
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SK285068B6 (sk) * 1997-09-29 2006-05-04 Nektar Therapeutics Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
CA2320219A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
WO1999066903A2 (en) * 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2366922C (en) * 1999-04-21 2008-07-22 1355540 Ontario Inc. Formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
WO2001045677A1 (en) 1999-12-20 2001-06-28 Kerkhof Nicholas J Process for producing nanometer particles by fluid bed spray-drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
ATE355849T1 (de) 2000-12-21 2007-03-15 Nektar Therapeutics Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
WO2005035088A2 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
AU2010252929B2 (en) * 2009-05-28 2015-08-27 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
EP2521538B1 (en) 2010-01-08 2018-10-24 Mallinckrodt Pharma IP Trading D.A.C. Dry powder fibrin sealant
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
CN103328499A (zh) 2010-11-01 2013-09-25 悉尼科技大学 免疫调节剂及其用途
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
MX342675B (es) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Formulaciones estables para inyeccion parenteral de farmacos de peptido.
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
AU2013246926B2 (en) 2012-04-13 2016-07-21 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
RU2640078C2 (ru) 2012-06-26 2017-12-26 ДжиИ Хелткер АС Получение композиции, содержащей микропузырьки газа
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CA2899032A1 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP4218742A1 (en) 2014-04-04 2023-08-02 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
ES2936067T3 (es) 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2016201248A1 (en) 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
WO2018075865A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions for the treatment of neurodegenerative diseases
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
ATE204750T1 (de) * 1992-06-12 2001-09-15 Teijin Ltd Pharmazeutische zubereitung zur anwendung in den atemwegen

Also Published As

Publication number Publication date
WO1996009814A1 (en) 1996-04-04
RU2147226C1 (ru) 2000-04-10
CA2199954A1 (en) 1996-04-04
BR9509171A (pt) 1997-09-16
AU701440B2 (en) 1999-01-28
HUT77373A (hu) 1998-03-30
EP0783298A1 (en) 1997-07-16
NZ292980A (en) 1999-02-25
ZA958239B (en) 1996-09-30
FI971332A (fi) 1997-04-01
PL319600A1 (en) 1997-08-18
NO971438L (no) 1997-03-26
AU3530295A (en) 1996-04-19
CZ92497A3 (en) 1997-08-13
JPH10506406A (ja) 1998-06-23
MX9702357A (es) 1997-06-28
NO971438D0 (no) 1997-03-26
FI971332A0 (fi) 1997-04-01

Similar Documents

Publication Publication Date Title
KR970705979A (ko) 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles)
RU97106769A (ru) Высушенные распылением микрочастицы как терапевтические носители
JP2914671B2 (ja) 薬剤組成物
KR970005305A (ko) 경비 투여용 제제(經鼻投與用製濟)
AU688566B2 (en) Drug delivery composition containing chitosan or derivative thereof having a defined z. potential
JP3414539B2 (ja) 経鼻吸収用組成物
JP2974409B2 (ja) 微粒子薬物組成物
JP3306779B2 (ja) 薬物送達組成物
JPH0696539B2 (ja) 関節の治療薬
WO1988009163A1 (en) Enhanced uptake drug delivery system
CN1120458A (zh) 生理活性肽组合物
JP2001508061A (ja) キトサン−ゼラチンa微粒子
JPH04247034A (ja) 鼻用医薬組成物
JP2802488B2 (ja) 経鼻吸収用生理活性ペプチド組成物
JPH07118164A (ja) 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物
WO1995028944A1 (en) Pharmaceutical inhalation compositions containing a solid active ingredient
EP0943336A1 (en) Peptide-containing pharmaceutical compositions for oral administration
CN1222310C (zh) 肝实质细胞增殖因子药用制剂
JP2002522507A (ja) 疾患状態の処置
JPH05170663A (ja) カルシトニン点鼻用医薬組成物
JPH07118170A (ja) 経鼻吸収薬物用キャリヤ、生理活性ペプチド組成物およびその製造法
JPH06293631A (ja) ケラチン加水分解物を担体として用いたドラッグデリバリーシステム
JP4671092B2 (ja) ウイルス感染予防および対策
JP2001526662A (ja) 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
JP3904268B2 (ja) Hgf医薬製剤

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid